Decision to fund methylnaltrexone in palliative care

PHARMAC

8 December 2017 - PHARMAC is pleased to announce the approval of an agreement with Link Pharmaceuticals Limited for the listing of methylnaltrexone bromide (Relistor) injection in Section B (Community) and Part II of Section H (Hospital) of the Pharmaceutical Schedule from 1 January 2018. 

Funding is subject to Special Authority criteria and DHB Hospital restrictions.

Read PHARMAC press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , New Zealand